Dow Corning Breast Implant Lawsuit: Bankruptcy and $3.2B Settlement

The Dow Corning breast implant lawsuit was a decades-long wave of product liability litigation against Dow Corning Corporation over its silicone gel breast implants. Women alleged the devices ruptured, leaked silicone into their bodies, and caused autoimmune and connective tissue diseases. The litigation pushed Dow Corning into Chapter 11 bankruptcy in 1995 and ended with a $3.2 billion settlement covering more than 170,000 women with breast implants and about 75,000 other silicone-device claimants. The company emerged from bankruptcy in 2004, and the settlement trust that paid the claims closed in March 2025.

What the Lawsuits Claimed

Silicone gel implants were first placed in a patient in 1962, and Dow Corning, a joint venture of Dow Chemical and Corning Incorporated, became the dominant manufacturer. When Congress passed the Medical Devices Amendment in 1976, implants were grandfathered as Class III devices and stayed on the market without the premarket approval process later required for new devices.¹

The core claim in the lawsuits was that silicone leaking or bleeding from the implants caused systemic disease, including lupus, rheumatoid arthritis, and connective tissue disorders. Plaintiffs also pointed to high rupture rates and to “gel bleed,” the seepage of silicone through an intact implant shell. Internal Dow Corning documents that surfaced during discovery suggested the company had been aware of both problems for years.¹ In February 1992, under FDA pressure, Dow Corning released internal memoranda acknowledging it had known for decades that silicone gel could seep from its implants, while maintaining that it did not believe the leakage caused health problems.²

The Verdicts That Broke the Dam

The first successful case came in 1977, when a Cleveland woman received a $170,000 settlement after her implants ruptured.¹²

Verdicts grew larger. In July 1991, Brenda Toole won $5.4 million in Alabama after silicone was found in her lymphatic system. That December, a federal jury in San Francisco returned the largest implant verdict to that point in Hopkins v. Dow Corning: $840,000 in compensatory damages and $6.5 million in punitive damages for Mariann Hopkins, with findings that the implant was defectively designed, that Dow Corning had failed to warn, and that the company had committed fraud.³ The Ninth Circuit upheld the verdict in August 1994, applying the delayed-discovery doctrine to toll the statute of limitations on the ground that Dow Corning had suppressed medical literature about the silicone-autoimmune link.⁴

Also in December 1991, Pamela Jean Johnson was awarded $25 million, including $20 million in punitive damages, against manufacturer MEC in a separate case. By 1992, Dow Corning, Bristol-Myers Squibb, and Bioplasty had exited the silicone breast implant business entirely.²

The FDA Moratorium

On January 6, 1992, FDA Commissioner David A. Kessler called for a voluntary moratorium on the distribution of silicone breast implants. “We want surgeons to stop using these implants in patients until this new evidence can be thoroughly evaluated,” Kessler said, adding that he could not “assure the safety of these devices at the present time.”⁵

The FDA then pulled silicone gel-filled implants from the general market. Access was limited to women undergoing breast reconstruction after mastectomy, correction of congenital deformities, or replacement of existing implants, and only through clinical studies designed to gather long-term safety data.⁶ For the next fourteen years, most American women seeking implants received saline-filled devices.

Class Action, Collapsed Settlement, and Bankruptcy

Federal lawsuits were consolidated for pretrial proceedings under the multidistrict litigation process. On June 25, 1992, the Judicial Panel on Multidistrict Litigation transferred the cases to the Northern District of Alabama under Chief Judge Sam C. Pointer Jr., creating In re Silicone Gel Breast Implant Products Liability Litigation, MDL-926. More than 21,000 cases were eventually transferred.⁷⁸

In September 1993, Dow Corning, Bristol-Myers Squibb, Baxter International, and 3M tentatively agreed to a $4.25 billion global settlement, then the largest class action settlement in history. Judge Pointer granted final approval in September 1994. The deal quickly unraveled: about 400,000 women filed claims, far more than negotiators had anticipated, and the fund could not accommodate them. Judge Pointer set a September 30, 1995 deadline for a replacement deal, warning that otherwise he would dissolve the class and release plaintiffs to sue individually.⁹

In May 1995, facing 20,000 active lawsuits and 410,000 potential claims, Dow Corning filed for Chapter 11 bankruptcy in the Eastern District of Michigan. The filing halted all pending litigation against the company.¹⁰ A revised global settlement was negotiated among 3M, Baxter, and Bristol-Myers Squibb without Dow Corning.¹¹

With Dow Corning shielded by bankruptcy, plaintiffs turned to its parent, Dow Chemical. In October 1995, a Nevada state jury found Dow Chemical liable for the injuries of Charlotte Mahlum, awarding $3.9 million in compensatory damages and $10 million in punitive damages, and concluding the company had “acted in conscious disregard of safety.”¹² In December 1998, the Nevada Supreme Court upheld the compensatory award on a negligent-undertaking theory, finding Dow Chemical had tested the toxicity of liquid silicone for Dow Corning and failed to disclose dangers its research had uncovered, including a 1956 study showing silicone migration to major organs and a 1970 pathology test in rats. The court reversed the $10 million punitive award.¹³

The $3.2 Billion Settlement

In July 1998, still in bankruptcy, Dow Corning reached a tentative $3.2 billion deal with plaintiffs.¹⁴ The settlement covered more than 170,000 women who had received breast implants and about 75,000 claimants with other silicone-based devices, including joint and facial implants.¹⁵

Under the reorganization plan, Dow Corning’s shareholders, Dow Chemical and Corning Inc., agreed to contribute more than $2.35 billion to the settlement fund without requiring claimants to prove that silicone had caused their claimed diseases, effectively waiving the right to contest causation.¹⁰ Compensation was tiered by the severity of the claimed condition:

$2,000 for an immediate cash-out with no disease claim.
$5,000 for implant removal surgery.
Up to $25,000 for a ruptured implant.
$10,000 to $300,000 for disease claims, with up to $300,000 for a severely debilitating illness.¹¹⁴

Claimants who did not accept the settlement kept the option to sue individually.¹⁴ After a group of Nevada women dropped their opposition, a federal judge gave final approval to the reorganization plan in April 2004. Dow Corning emerged from bankruptcy on June 1, 2004, nine years after filing.¹⁵

What the Science Later Found

The scientific case behind the verdicts weakened as independent research accumulated. In 1994, a Mayo Clinic study in the New England Journal of Medicine found no increased risk of connective tissue disease in women with silicone gel implants; a 1995 follow-up reached the same conclusion. That year the American College of Rheumatology called the evidence “compelling” that implants posed “no demonstrable risk” for connective tissue or rheumatic disease. In 1996, a federal judge in Oregon ruled that the plaintiffs’ scientific evidence linking implants to disease was invalid.²

Judge Pointer appointed a National Science Panel to review the literature. In December 1998, the panel concluded that the scientific evidence failed to show that silicone implants cause disease.¹¹ In June 1999, the Institute of Medicine issued a 400-page report finding that while implants could cause localized complications such as hardening or scarring of breast tissue, they did not cause lupus, rheumatoid arthritis, or other systemic autoimmune conditions.² Billions had been paid on a theory of harm that independent science could not confirm.

Silicone Implants Return to the Market

In November 2006, the FDA approved silicone gel-filled implants for return to the American market, granting premarket approval to Allergan (formerly Inamed) and Mentor Corporation for both augmentation and reconstruction. Both companies were required to conduct 10-year post-approval studies and large-scale studies of rare adverse events. The FDA cited its extensive scientific review, including the Institute of Medicine’s 1999 findings, in concluding the benefits outweighed the risks.¹⁶

The FDA has stated that it has “not detected any association between silicone gel-filled breast implants and connective tissue disease, breast cancer or reproductive problems,” while acknowledging that existing studies may not be large or long enough to fully address all concerns. The agency has separately recognized breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare cancer that can develop in the scar tissue around implants, as a distinct risk.¹⁷

The Trust Closes

The Settlement Facility for the Dow Corning Trust processed claims for two decades after the company emerged from bankruptcy. The final deadline for submitting disease, expedited release, and increased severity claims was June 3, 2019. On December 30, 2024, the Eastern District of Michigan entered an order approving termination of the Settlement Program and Trust, finding that the conditions for termination under the 2004 reorganization plan had been met. The facility completed its wind-down by the end of March 2025, closing its offices, website, and email addresses. According to the facility, all claims were evaluated and all approved claims were paid.¹⁸

One dispute is still open. A group of 2,616 Korean claimants alleges the Settlement Facility failed to pay more than $6 million in approved claims, saying their claims were improperly denied because of address verification and international mail problems. The Sixth Circuit affirmed the district court’s termination order in April 2025, ruling that the Korean claimants’ challenges were beyond the scope of the reorganization plan. The claimants have petitioned the U.S. Supreme Court for review, and the petition remained pending as of the most recently available filings. Dow Silicones Corporation, the sole remaining respondent, has argued the petition should be denied as a contract-interpretation dispute unsuitable for Supreme Court review.¹⁹²⁰

1
PBS. Breast Implants on Trial: Chronology
2
AMA Journal of Ethics. Silicone Breast Implant Litigation
3
Los Angeles Times. Breast Implant Suit Verdict
4
Justia. Hopkins v. Dow Corning Corporation, 33 F.3d 1116
5
Washington Post. FDA Urges a Moratorium on Silicone Breast Implants
6
FDA. Update on the Safety of Silicone Gel-Filled Breast Implants
7
Federal Judicial Center. Science in the Courtroom: The Silicone Gel Breast Implant Litigation
8
U.S. District Court, Northern District of Alabama. MDL 926 Opinion
9
New York Times. A Judge and a Deadline: The Breast Implant Case
10
U.S. District Court, Eastern District of Michigan. Dow Corning Bankruptcy Opinion
11
PBS. Breast Implants on Trial: Chronology
12
Los Angeles Times. Dow Chemical Found Liable in Implant Case
13
FindLaw. Dow Chemical Co. v. Mahlum
14
Los Angeles Times. Dow Corning Settlement Reached
15
NBC News. Dow Corning Emerges From Bankruptcy
16
Cancer Network. FDA Approves Two Silicone Gel-Filled Breast Implants
17
FDA. Risks and Complications of Breast Implants
18
Claimants’ Advisory Committee. Claimants’ Advisory Committee
19
U.S. Supreme Court. Petition for Writ of Certiorari, No. 25-128
20
U.S. Supreme Court. Brief in Opposition, No. 25-128